Amarin Corp Plcuk (AMRN) Total Non-Current Liabilities (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Total Non-Current Liabilities of $185.2 million for Q1 2026, up 8.74% year-over-year from $170.3 million in Q1 2025, and down 7.63% quarter-over-quarter from $200.5 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Total Non-Current Liabilities data on file, last reported at $185.2 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $185.2 million, up 8.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $185.2 million (up 8.74% YoY), and the FY2025 annual result was $200.5 million, up 6.86% from the prior year.
- Total Non-Current Liabilities slipped to $185.2 million in Q1 2026 per AMRN's latest filing, from $200.5 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $385.6 million in Q2 2022 and troughed at $170.3 million in Q1 2025.
- A 5-year average of $247.8 million and a median of $238.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities plunged 30.63% in 2024, then gained 8.74% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $282.6 million in 2022, then retreated by 4.29% to $270.5 million in 2023, then sank by 30.63% to $187.7 million in 2024, then climbed by 6.86% to $200.5 million in 2025, then dropped by 7.63% to $185.2 million in 2026.
- Business Quant data shows AMRN's Total Non-Current Liabilities at $185.2 million in Q1 2026, $200.5 million in Q4 2025, and $189.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -31.03 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 185.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 185.23 Mn |
| Dec 31, 2025 | 200.54 Mn |
| Sep 30, 2025 | 188.96 Mn |
| Jun 30, 2025 | 193.28 Mn |
| Mar 31, 2025 | 170.35 Mn |
| Dec 31, 2024 | 187.67 Mn |
| Sep 30, 2024 | 209.77 Mn |
| Jun 30, 2024 | 238.64 Mn |
| Mar 31, 2024 | 234.88 Mn |
| Dec 31, 2023 | 270.52 Mn |
| Sep 30, 2023 | 278.61 Mn |
| Jun 30, 2023 | 283.74 Mn |
| Mar 31, 2023 | 266.79 Mn |
| Dec 31, 2022 | 282.64 Mn |
| Sep 30, 2022 | 310.78 Mn |
| Jun 30, 2022 | 385.56 Mn |
| Mar 31, 2022 | 325.11 Mn |
| Dec 31, 2021 | 393.32 Mn |
| Sep 30, 2021 | 387.96 Mn |
| Jun 30, 2021 | 394.14 Mn |